Effect of High-Carbohydrate Diet on Plasma Metabolome in Mice with Mitochondrial Respiratory Chain Complex III Deficiency.
Study Goal
The researchers aimed to determine if a high-carbohydrate diet (60% dextrose) could alleviate hypoglycemia and improve survival in a mouse model of GRACILE syndrome, a mitochondrial disorder.
Results Summary
The high-carbohydrate diet reduced survival in the affected mice and did not improve hypoglycemia or liver glycogen depletion, though it normalized some metabolic indicators of liver mitochondrial dysfunction.
Population
Knock-in (Bcs1lc.232A>G) mouse model of GRACILE syndrome.
Effective Dosage
60% dextrose diet.
Duration
Until death (mean survival 29 days on HCD vs. 33 days on standard diet).
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
high-carbohydrate diet (HCD, 60% dextrose) | decrease | survival | homozygous knock-in (Bcs1lc.232A>G) mice (model of GRACILE syndrome) | 29 ± 2.5 days vs 33 ± 3.8 days on standard diet | shorter survival | #1 |
high-carbohydrate diet (HCD, 60% dextrose) | no change | hypoglycemia | homozygous knock-in (Bcs1lc.232A>G) mice (model of GRACILE syndrome) | - | no improvement | #2 |
high-carbohydrate diet (HCD, 60% dextrose) | no change | liver glycogen depletion | homozygous knock-in (Bcs1lc.232A>G) mice (model of GRACILE syndrome) | - | no improvement | #3 |
high-carbohydrate diet (HCD, 60% dextrose) | increase | several amino acids and urea cycle intermediates | homozygous knock-in (Bcs1lc.232A>G) mice (model of GRACILE syndrome) | - | increased | #4 |
high-carbohydrate diet (HCD, 60% dextrose) | decrease | arginine, carnitines, succinate, and purine catabolites | homozygous knock-in (Bcs1lc.232A>G) mice (model of GRACILE syndrome) | - | decreased | #5 |
high-carbohydrate diet (HCD, 60% dextrose) | no change | increase in aromatic amino acids (indicator of liver mitochondrial dysfunction) | homozygous knock-in (Bcs1lc.232A>G) mice (model of GRACILE syndrome) | - | normalized | #6 |
high-carbohydrate diet (HCD, 60% dextrose) | no change | glycine, serine and threonine metabolism | homozygous knock-in (Bcs1lc.232A>G) mice (model of GRACILE syndrome) | - | partly normalized | #7 |
high-carbohydrate diet (HCD, 60% dextrose) | no change | phenylalanine and tyrosine metabolism | homozygous knock-in (Bcs1lc.232A>G) mice (model of GRACILE syndrome) | - | partly normalized | #8 |
high-carbohydrate diet (HCD, 60% dextrose) | no change | urea cycle | homozygous knock-in (Bcs1lc.232A>G) mice (model of GRACILE syndrome) | - | partly normalized | #9 |
Mitochondrial disorders cause energy failure and metabolic derangements. Metabolome profiling in patients and animal models may identify affected metabolic pathways and reveal new biomarkers of disease progression. Using liver metabolomics we have shown a starvation-like condition in a knock-in (Bcs1lc.232A>G) mouse model of GRACILE syndrome, a neonatal lethal respiratory chain complex III dysfunction with hepatopathy. Here, we hypothesized that a high-carbohydrate diet (HCD, 60% dextrose) will alleviate the hypoglycemia and promote survival of the sick mice. However, when fed HCD the homozygotes had shorter survival (mean ± SD, 29 ± 2.5 days, n = 21) than those on standard diet (33 ± 3.8 days, n = 30), and no improvement in hypoglycemia or liver glycogen depletion. We investigated the plasma metabolome of the HCD- and control diet-fed mice and found that several amino acids and urea cycle intermediates were increased, and arginine, carnitines, succinate, and purine catabolites decreased in the homozygotes. Despite reduced survival the increase in aromatic amino acids, an indicator of liver mitochondrial dysfunction, was normalized on HCD. Quantitative enrichment analysis revealed that glycine, serine and threonine metabolism, phenylalanine and tyrosine metabolism, and urea cycle were also partly normalized on HCD. This dietary intervention revealed an unexpected adverse effect of high-glucose diet in complex III deficiency, and suggests that plasma metabolomics is a valuable tool in evaluation of therapies in mitochondrial disorders.